Name

Extractas Bioscience

Legal name

Tasmanian Alkaloids Pty Ltd T/A Extractas Bioscience

Website

https://extractas.com.au

Company type

Private

Founded year

1975

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Westbury

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Alkaloid Raw Materials (ARM) Sales: Production and sale of alkaloid raw materials including Thebaine, Codeine, Oripavine, and Noscapine to global pharmaceutical manufacturers. These are starting materials for pain-relieving APIs, abuse deterrent formulations, and cough-suppressant medications.
2. Botanical Extracts and Specialty Ingredients: Customized botanical extraction capabilities and specialty ingredients including poppy seeds (culinary and non-culinary), with products tailored to customer specifications.
3. Contract Manufacturing Services: GMP pharmaceutical manufacturing services including analytical services, R&D, regulatory affairs support, and process development for customers from seed to finished products.
4. Analytical Standards and Regulatory Dossier Support: Supply of analytical standards and 'plug and play' regulatory dossier sections to pharmaceutical customers.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Extractas Bioscience produces and supplies alkaloid raw materials (ARM) — including Thebaine, Codeine, Oripavine, and Noscapine — extracted from its patented Papaver somniferum poppy chemotypes for sale to global pharmaceutical manufacturers. The company also provides customized botanical extraction, synthetic manufacturing, analytical, and regulatory dossier support services on a B2B contract basis, operating GMP-compliant manufacturing at its Westbury, Tasmania facility.

Product overview

Extractas Bioscience is a fully integrated research and manufacturing company offering a portfolio of botanical extracts and purified products for the pharmaceutical industry. The core product line is Alkaloid Raw Materials (ARM) — concentrated poppy straw products including Thebaine, Codeine, Oripavine, and Noscapine — derived from patented poppy chemotypes. The company also produces culinary and non-culinary poppy seeds, medical-grade hand sanitiser, and land/soil conditioner from extraction by-products. Services include botanical extraction capabilities (from kg-lab scale to 35+ tonnes/day), synthetic manufacturing, analytical services with validated methods, and comprehensive regulatory/dossier support. The company operates from Tasmania, Australia, with manufacturing facilities in Westbury.

Differentiator

Problem solved

Functional benefit

Products and services

• Alkaloid Raw Materials (ARM) Concentrated poppy straw products extracted from patented Papaver somniferum chemotypes, supplied to global pharmaceutical manufacturers as starting materials for pain-relieving APIs, abuse-deterrent formulations, and cough-suppressant medications.
• Thebaine Alkaloid raw material extracted from a patented high-thebaine poppy variety, used as a starting material for pain-relieving and abuse-deterrent Active Pharmaceutical Ingredients (APIs).
• Codeine Naturally sourced Codeine produced from a patented high-codeine poppy variety, supplied to global pharmaceutical manufacturers for pain-relief medications.
• Oripavine Alkaloid raw material primarily used to produce the Nal family of APIs including Naloxone and Naltrexone, used as abuse-deterrent pharmaceuticals.
• Noscapine One of the world's largest produced Noscapine supplies, an alkaloid primarily used for its antitussive (cough-suppressing) effects in pharmaceutical preparations.
• Culinary Poppy Seed Poppy seeds processed through sieves, aspirators and gravity tables, bulk packaged and delivered to European partners for distribution into confection, spice and bakery industries.
• Non-Culinary Poppy Seed Processed poppy seeds yielding products including biodiesel, furnace fuel, paint oil, and poppy meal used as agricultural fertiliser.
• Medical Grade Hand Sanitiser TGA-registered medical grade hand sanitiser (Ethanol 80%) produced using the company's chemical manufacturing capabilities, compliant with WHO recommended formulation.
• Land and Soil Conditioner Compressed and heat-treated poppy straw husk material (spent marc) distributed as a land and soil conditioner by approved agricultural customers.
• Botanical Extraction Services Customised botanical extraction capabilities ranging from boutique small-scale extraction (kg-lab scale) through to high-volume biomass extraction exceeding 35 tonnes per day, offered on a contract basis.
• Synthetic Manufacturing Services Synthetic manufacturing services tailored to customer product requirements and specifications, supporting pharmaceutical customers from seed to finished product.
• Analytical Services Fully validated analytical methods, comprehensive technical packages, and analytical standards supplied to pharmaceutical customers for ARM products.
• Regulatory Support Services Comprehensive DMF and regulatory dossier information, including analytical standards and 'plug and play' regulatory submission sections supplied to pharmaceutical customers.

Quantifiable outcome

• Largest global producer of Thebaine and natural Codeine
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

• Siegfried Holding AGflagshipStrategic or Co-development Partner · 27 January 2026Extractas Bioscience was acquired by Siegfried, a Swiss-listed global Contract Development and Manufacturing Organization (CDMO), as part of a strategic exit by SK Capital Partners. The acquisition included three manufacturing sites (Noramco in Wilmington, Delaware; Purisys in Athens, Georgia; Extractas Bioscience in Tasmania) adding approximately 400 employees. The transaction supports Siegfried's EVOLVE+ strategy and expands its US-based manufacturing capacity.
• Tasmanian Grower NetworkcoreStrategic or Co-development PartnerPartnership with the most productive and technologically advanced growers across Tasmania and other parts of the world. The success of the 'factory in the field' strategy is born from the partnership nurtured between the Grower base, their highly productive land, and Extractas' Agricultural support team, delivering specific compounds, increased yield and highest quality.
• European Poppy Seed PartnercoreChannel Partner/ Reseller/ DistributorLong-term partnership with European-based partner for culinary poppy seed distribution. Poppy seeds are bulk packaged and delivered to the European partner who further cleans and blends for distribution into confection, spice and bakery industries globally.
• M2 LogisticsminorStrategic or Co-development PartnerDuring the COVID-19 pandemic, Extractas partnered with Tasmanian business M2 Logistics to manufacture medical grade Hand Sanitiser and surface cleaning agents for distribution into Australian markets, utilizing Extractas' TGA-registered manufacturing facility and chemical production capabilities.
• University of TasmaniacoreStrategic or Co-development PartnerOngoing partnership supporting science education through scholarships (Brian Hartnett Scholarship in Science Teaching, Tasmanian Alkaloids Honours Scholarship in Chemistry, West North-West Bursary) and providing work experience opportunities for students in Agricultural Research and Development.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Macfarlan Smith (Johnson Matthey): UK-based manufacturer of opiate alkaloids and controlled-substance APIs operating as part of Johnson Matthey's Health division; competes directly with Extractas in the supply of morphine, codeine, and thebaine to global pharmaceutical customers.
• Mallinckrodt Pharmaceuticals: Global specialty pharmaceutical company with significant opiate API production and finished-dose pain management products; directly comparable in supplying controlled-substance pharmaceutical ingredients to global drug manufacturers.
• Noramco: US-headquartered producer of opiate alkaloid raw materials and APIs; was acquired alongside Extractas Bioscience by Siegfried in 2026 and is now a sister company with overlapping product portfolio (thebaine, codeine, controlled-substance APIs).
• Alcaliber: Spanish producer of alkaloid raw materials and opiate APIs from poppy cultivation; competes with Extractas in the global alkaloid supply market with comparable extraction capabilities and pharmaceutical-grade output.
• Purisys: US-based API manufacturer specializing in controlled substances and niche pharmaceutical ingredients; acquired together with Extractas by Siegfried in 2026, making it a sister company with comparable botanical/API manufacturing capabilities.

Broad incumbents

• Siegfried Holding AG: Swiss-listed global CDMO and Extractas' parent company since May 2026; offers broader pharmaceutical API and finished-dose manufacturing services across multiple chemistries, of which Extractas' botanical/alkaloid work is now one specialized piece.
• Lonza Group: Swiss global CDMO with extensive API and biopharmaceutical manufacturing capabilities; comparable as a broad incumbent serving the same pharmaceutical customer base with overlapping API manufacturing services, though not focused on alkaloid extraction.
• Johnson & Johnson (Janssen): Former owner of Extractas (1982-2016) through its Worldwide Narcotics Franchise and a major buyer of pharmaceutical-grade alkaloids; comparable as a large incumbent pharmaceutical manufacturer with downstream demand for the same controlled-substance APIs Extractas produces.
• Albemarle Corporation: Global specialty chemicals company with a Fine Chemistry Services segment producing controlled substances and pharmaceutical intermediates; comparable as a broader chemical manufacturer serving pharma with overlapping regulatory complexity.

Emerging players

• Almac Group: UK/Ireland-headquartered pharmaceutical services company offering API development, manufacturing, and analytical services; partial overlap with Extractas in custom pharmaceutical manufacturing and analytical/regulatory support services for controlled substances.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/extractasbioscience

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Extractas Bioscience